Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

NW Clarke ; A Ali ; FC Ingleby ORCID logo ; A Hoyle ; CL Amos ; G Attard ; CD Brawley ; J Calvert ; S Chowdhury ; A Cook ; +41 more... W Cross ; DP Dearnaley ; H Douis ; D Gilbert ; S Gillessen ; RJ Jones ; RE Langley ; A MacNair ; Z Malik ; MD Mason ; D Matheson ; R Millman ; CC Parker ; AWS Ritchie ; H Rush ; JM Russell ; J Brown ; S Beesley ; A Birtle ; L Capaldi ; J Gale ; S Gibbs ; A Lydon ; A Nikapota ; A Omlin ; JM O'Sullivan ; O Parikh ; A Protheroe ; S Rudman ; NN Srihari ; M Simms ; JS Tanguay ; S Tolan ; J Wagstaff ; J Wallace ; J Wylie ; A Zarkar ; MR Sydes ; MKB Parmar ; ND James ; STAMPEDE investigators ; (2020) Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. ANNALS OF ONCOLOGY, 31 (3). 442-. ISSN 0923-7534 DOI: 10.1016/j.annonc.2020.01.002
Copy

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.
Item Type Article
Elements ID 144961
Date Deposited 15 Jan 2021 14:50

Explore Further

picture_as_pdf
PIIS0923753420359202.pdf
subject
Published Version
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads